Senior Scientist

Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro’s lead program is for Urea Cycle Disorders. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.  

We are collaborative and united by a common mission. We are building a company with extraordinary people with an audacious vision to create transformative genetic medicines for prevalent diseases. Our values - Rewrite the future, On the Cutting Edge, Better Together, Dynamically Different, Kindness and Integrity form the fabric of the organization. They are reinforced daily and serve as key dimensions in the hiring process to help us ensure that Korro is a magnet for outstanding talent and a great place to work. Join us as we redefine what's possible in genetic medicine and work to make a lasting impact on human health. 

Korro Bio is seeking an experienced Senior Scientist to lead our HTS-NGS team in support of our oligonucleotide platform and portfolio projects. This is a hybrid leadership and hands-on role that requires a combination of scientific expertise, team management, and cross-functional collaboration. The ideal candidate brings deep technical knowledge in high-throughput cell assays and NGS workflows, along with leadership experience, to lead a key workflow in the identification of RNA editing therapeutics.

PhD with 4+ years, MS with 12+ years or equivalent industry experience in cell biology, molecular biology, genomics, or a related field.

Prior experience in a biotech or pharmaceutical environment is required.

Demonstrated track record of managing scientists to achieve research and operational goals.

Hands-on expertise with cell culture in 96- and 384-well formats, including transfection methodologies.

Comprehensive end-to-end NGS experience: amplicon-seq, RNA-seq, library preparation, QC, and sequencing run execution.

Expertise with Illumina sequencing platforms preferred (MiSeq).

Expertise in core molecular biology techniques: RNA/DNA isolation, PCR/qPCR, and gel electrophoresis.

Experience with liquid handling automation systems, including Viaflo 96/384, HiRes/Certus Flex, and/or Tempest.

LIMS experience, preferably with Benchling.

Exceptional attention to detail and commitment to data quality and scientific reproducibility.

Strong written and verbal communication skills; ability to distill complex technical information for diverse audiences.

Collaborative team player who thrives in a dynamic, cross-functional biotech environment.

Experience with project management tools such as Jira and Confluence.

Familiarity with QC instrumentation: Qubit, TapeStation, and Fragment Analyzer.

Experience with screening siRNA, antisense oligonucleotides, or similar constructs a strong plus.

Korro offers competitive total rewards package, including equity-based compensation, and a comprehensive benefits package that includes medical, dental, vision, 401(k) retirement plan, life insurance, a dependent care flexible spending account and a Company-funded health savings account and free parking.